查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001151

生技药品合约开发市场：按服务类型、分子类型、治疗领域、宿主系统、技术和最终用户划分－2026-2032年全球市场预测

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生技药品合约开发市场价值将达到 81.7 亿美元，到 2026 年将成长至 91.5 亿美元，到 2032 年将达到 182.9 亿美元，复合年增长率为 12.18%。

主要市场统计数据
基准年 2025 81.7亿美元
预计年份：2026年 91.5亿美元
预测年份 2032 182.9亿美元
复合年增长率 (%) 12.18%

为企业主管介绍生物製药合约开发 (CDO) 的发展趋势，概述技术、法规和采购方案的策略重点。

生物製药合约开发（CTD）领域正经历着重大变革，其驱动力包括科学创新、不断变化的监管预期以及研发和生产能力获取与部署方式的重组。本报告整合了塑造该领域的核心趋势，并提出了经营团队应纳入短期规划和长期能力建设的策略考量。报告还重点阐述了技术进步、供应链韧性以及内部研发与外部合约伙伴关係之间不断变化的平衡之间的相互关係。

从前瞻性的角度看待重组生物製剂合约开发和生产所需的技术、商业性和结构变革。

生物製药研发生态系统正经历技术、商业性和结构上的同步变革，改变了其在整个价值链中的竞争地位。在技​​术层面，连续生产方法和一次性系统的应用正在重新定义製程架构和设施布局，从而提高了产能利用的柔软性，并加快了产品宣传活动之间的切换。这些技术变革与更先进的上游和下游研发技术相辅相成，需要整合製程知识和能力，以确保大规模生产出品质稳定可靠的产品。

对 2025 年美国关税调整将如何影响生物製药开发中的采购、供应链设计和位置决策进行详细分析。

2025年新增关税的实施以及贸易政策的调整，为参与生物製药合约开发的机构带来了新的营运和策略考量。关税变化将影响专用设备、一次性组件和关键原材料的进出口，可能增加采购计划的复杂性，并要求更稳健的供应商多元化策略。因此，製造商和赞助商正在重新审视其供应商组合和库存策略，以保护其研发项目免受关税波动的影响。

基于全面细分的洞察，揭示了服务类型、分子类别、治疗领域、宿主系统、最终用户和底层技术的能力差距和策略重点。

精细的市场区隔观点揭示了服务类型、分子类别、治疗领域、宿主系统、终端使用者和底层技术等方面的能力差距与策略机会的交会点。基于服务类型，市场涵盖临床生产、商业化生产、灌装包装和製程开发。临床生产本身涵盖I期、II期和III期临床试验，而製程开发则分为下游开发和上游工程开发。这种细分凸显了合作伙伴的重要性，他们能够无缝管理从早期製程表征到后期放大生产和商业化的计划，确保分析方法、可比性策略和品质系统的连续性。

涵盖美洲、欧洲、中东和非洲以及亚太地区的生产能力优势、监管细微差别和供应链优势的战略区域资讯。

区域趋势持续影响着生物製药研发活动的集中地点以及企业建构全球营运的方式。在美洲，密集的创新中心和临床试验生态系统持续推动对临床生产和快速分析的需求。同时，法律规范强调资料完整性和流程验证实践，从而支持加速研发。该地区还受益于毗邻主要赞助商和创业投资的地理优势，这增强了其早期专案储备，这些专案需要专业的合约开发支援。

关于技术投资、监管合规深度和地理覆盖范围如何使合约开发和生产组织 (CDMO) 产生差异化的关键竞争考察。

合约研发生产机构 (CDMO) 之间的竞争格局取决于其技术平台的差异化、监管合规经验的深度以及所提供的综合服务的广度。领先的供应商优先投资于先进的分析技术、可扩展的一次性系统和製程改进技术，以缩短週期并提高产品品质的一致性。这些投资通常辅以策略伙伴关係和能力协同开发安排，加速获得新的检测方法和分析技术。

为产业领导者提供切实可行的策略建议，以协调技术投资、营运韧性和伙伴关係模式，从而实现可扩展的生物製药开发。

产业领导者必须采取切实可行的策略，在创新速度和营运稳健性之间取得平衡，从而在生物製药开发中创造价值。应优先制定技术路线图，该路线图应结合对不銹钢系统的选择性投资（前提是资本支出能够透过长期大规模生产来证明），同时保持连续加工和一次性使用柔软性之间的平衡。将这些技术选择与产品系列和预期生命週期要求相匹配，将避免资产閒置，并确保可扩展的生产能力。

透明、多方面的调查方法，结合专家访谈、技术文献整合和营运评估，确保分析结果具有可操作性。

本分析的研究途径结合了定性专家访谈、技术文献整合和跨部门营运评估，旨在提供可靠且可操作的观点。关键资讯来源包括与製程开发科学家、生产负责人、法规事务专家和供应链专家的讨论，这些讨论提供了关于当前挑战、应用模式和区域营运差异的第一手见解。这些对话旨在揭示临床和商业化阶段的战术性和战略挑战。

权威的综合分析报告重点指出了领导者应关注的关键领域，以确保生物製药开发途径稳健、扩充性且具有商业性可行性。

总之，生物製药合约开发（CTD）环境正处于一个转折点，技术创新、监管复杂性和地缘政治变化相互交织，迫使战略决策重组。能够将技术投资与产品剂型要求相匹配、加强跨职能管治并实现价值链多元化的申办方和供应商，将能够以更高的灵活性和更低的营运风险顺利度过这一阶段。能否制定一个整合製程开发、临床生产和商业化准备的连贯专案计划，将决定哪些机构能够加快开发进度并实现价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生技药品合约开发市场：依服务类型划分

  • 临床生产
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业生产
  • 灌装/包装
  • 製程开发
    • 下游开发
    • 上游工程开发

第九章：按分子类型分類的生技药品合约开发市场

  • 细胞和基因治疗
  • 单株抗体
    • 双重特异性
    • 组合型
    • 不合格的
  • 重组蛋白
  • 疫苗
    • 细菌
    • mRNA
    • 病毒性的

第十章：生技药品合约开发市场：依治疗领域划分

  • 自体免疫疾病
  • 循环系统
  • 感染疾病
    • 细菌
    • 病毒性的
  • 肿瘤学
    • 血液学
    • 固体癌

第十一章：按宿主系统分類的生技药品合约开发市场

  • 哺乳动物
    • Cho 细胞
    • NS0细胞
  • 微生物
  • 酵母菌

第十二章：生技药品合约开发市场：依技术划分

  • 连续製造
    • 灌注
    • 单一途径
  • 免洗系统
  • 不銹钢系统

第十三章：生技药品合约开发市场：依最终用户划分

  • 生物製药公司
  • 契约製造组织
  • 製药公司

第十四章：生技药品合约开发市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：生技药品合约开发市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：生技药品合约开发市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国生技药品合约开发市场

第十八章：中国生技药品合约开发市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JRS PHARMA GmbH & Co. KG
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.
Product Code: MRR-957C47F8FF75

The Biologics Contract Development Market was valued at USD 8.17 billion in 2025 and is projected to grow to USD 9.15 billion in 2026, with a CAGR of 12.18%, reaching USD 18.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.17 billion
Estimated Year [2026] USD 9.15 billion
Forecast Year [2032] USD 18.29 billion
CAGR (%) 12.18%

An executive introduction to the evolving biologics contract development landscape that frames strategic priorities across technology, regulation, and sourcing choices

The biologics contract development landscape is undergoing a profound transformation driven by scientific innovation, evolving regulatory expectations, and a reconfiguration of how development and manufacturing capacity are sourced and deployed. This introduction synthesizes the core dynamics shaping the sector, framing the strategic considerations that executive teams must integrate into near-term planning and longer-term capability building. It clarifies the interplay between technological advances, supply chain resilience, and the shifting balance between in-house development and outsourced partnerships.

Emerging therapeutic modalities, including advanced cell and gene therapies alongside increasingly complex monoclonal antibody constructs, are altering process demands and facility designs. Concurrently, manufacturers and developers face heightened scrutiny around product quality, comparability, and regulatory compliance, which in turn elevates the value of experienced contract development partners who can navigate technical risk while compressing timelines. As a result, leaders must reassess sourcing strategies to prioritize partners capable of delivering end-to-end solutions spanning process development, clinical manufacturing, and commercial-scale production.

This introduction also recognizes the macroeconomic and policy factors that intersect with operational realities. Trade policy shifts, regional incentives, and capital allocation patterns will influence where capacity is expanded and what technologies receive preferential investment. Together, these forces create both opportunities for differentiation and pressure to accelerate capability development. The following sections unpack these shifts in greater detail to inform pragmatic choices for executives seeking to sustain momentum in biologics development and commercialization.

A forward-looking examination of the technical, commercial, and structural transformations reshaping contract development and manufacturing for biologics

The biologics development ecosystem is experiencing transformative shifts that are simultaneously technical, commercial, and structural, altering competitive positioning across the value chain. On the technical front, continuous manufacturing approaches and single-use system adoption are redefining process architectures and facility footprints, enabling greater flexibility in capacity utilization and faster changeovers between product campaigns. These technology shifts coincide with more sophisticated upstream and downstream development techniques that demand integrated process knowledge and capability to ensure consistent quality attributes at scale.

Commercially, the rise of complex modalities such as cell and gene therapies has expanded demand for bespoke development pathways and tightly coordinated clinical manufacturing services. This has elevated the strategic importance of partners that can provide not only manufacturing capacity but also deep regulatory and analytical expertise. In parallel, payer scrutiny and lifecycle management strategies are prompting sponsors to rethink commercialization plans early in development, which favors contract partners aligned to long-term product strategies rather than transactional suppliers.

Structurally, consolidation among certain segments and the growth of specialist niche providers are reshaping the supplier landscape. Firms that can offer integrated process development, clinical manufacturing support across multiple phases, and rapid scale-up to commercial manufacturing will hold a competitive edge. Meanwhile, geopolitical uncertainty and supply chain fragility are driving a renewed focus on regional diversification and nearshoring of critical capabilities. Taken together, these transformative shifts require leaders to re-evaluate partnerships, invest selectively in strategic technologies, and build adaptive governance models to manage complexity and accelerate time to clinic and market.

An in-depth analysis of how the 2025 United States tariff adjustments alter procurement, supply chain design, and location decisions for biologics development

The introduction of additional tariff measures and trade policy recalibrations in 2025 has introduced new operational and strategic considerations for organizations engaged in biologics contract development. Tariff changes affect inbound and outbound flows of specialized equipment, single-use components, and critical raw materials, which can increase the complexity of procurement planning and necessitate more robust supplier diversification strategies. Consequently, manufacturers and sponsors are reassessing vendor portfolios and inventory policies to insulate development programs from tariff-driven volatility.

Beyond direct cost implications, tariffs influence decisions about manufacturing location and capital deployment. Assumptions about the comparative advantage of particular regions for sourcing equipment or consumables must be revisited in light of altered cost structures and customs procedures. Firms with flexible manufacturing architectures, including capabilities for modular facility deployment and adaptable process platforms, are better positioned to respond to these shifts. Moreover, tariff-driven changes to supply chains amplify the importance of local regulatory familiarity and established logistics pathways, which can reduce lead times and the operational risks associated with cross-border movement of biologics materials.

Regulatory and contractual frameworks also require closer attention. Service agreements and supplier contracts may need renegotiation to account for tariff pass-through clauses, lead-time adjustments, and contingency provisions. Industry leaders are therefore strengthening cross-functional teams that include procurement, legal, regulatory, and operations professionals to ensure coherent responses to tariff impacts. In sum, while tariffs do not alter the fundamental scientific challenges of biologics development, they reshape the economics and risk profile of sourcing, capacity planning, and long-term strategic investments.

Comprehensive segmentation-driven insights that reveal capability gaps and strategic priorities across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies

A nuanced segmentation lens reveals where capability gaps and strategic opportunities converge across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies. Based on service type, the market encompasses clinical manufacturing, commercial manufacturing, fill-finish, and process development; clinical manufacturing itself spans Phase I, Phase II, and Phase III, while process development divides into downstream development and upstream development. This segmentation highlights the need for partners who can move projects seamlessly from early-phase process characterization through late-stage scale-up and commercial transfer, ensuring continuity of analytical methods, comparability strategies, and quality systems.

Based on molecule type, the landscape includes cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccines; within monoclonal antibodies, bispecific, conjugated, and naked formats present varying process and analytical challenges, and vaccines differentiate across bacterial, mRNA, and viral platforms. These distinctions drive divergent technical requirements-cell and gene therapies require specialized viral vector production and cold chain logistics, bispecific antibodies often demand advanced purification and potency assays, and mRNA vaccines hinge on lipid nanoparticle formulation and stringent RNA integrity controls-thereby influencing supplier capability priorities and facility design.

Based on therapeutic area, the market covers autoimmune disorders, cardiovascular, infectious diseases, and oncology; infectious diseases further split into bacterial and viral categories, while oncology divides into hematology and solid tumors. Therapeutic focus affects clinical manufacturing cadence, batch sizes, and development timelines; oncology programs, particularly in hematology, may require rapid iterative production for personalized therapies, whereas infectious disease vaccine campaigns often prioritize surge capacity and platform scalability.

Based on host system, host options include mammalian, microbial, and yeast; mammalian systems further specify CHO cells and NS0 cells, and microbial systems highlight E. coli. Host selection informs upstream process configuration, contamination control regimes, and downstream purification strategies, with mammalian hosts typically used for complex glycosylated proteins and microbial hosts offering cost-effective expression for certain recombinant products.

Based on end user, the market serves biopharmaceutical companies, contract manufacturing organizations, and pharmaceutical companies; understanding end-user needs clarifies service packaging, from flexible clinical supply arrangements for small biotech sponsors to integrated, regulatory-ready commercial supply chains for larger developers. Finally, based on technology, capabilities range across continuous manufacturing, single-use systems, and stainless steel systems, with continuous manufacturing itself encompassing perfusion and single-pass modalities. Technology selection affects facility footprint, capital intensity, and operational throughput, and it often determines the speed at which a partner can support transitions between clinical and commercial phases. Collectively, these segmentation dimensions underscore the imperative for strategic alignment between sponsor programs and partner capabilities to minimize technical risk and optimize development timelines.

Strategic regional intelligence that maps capacity strengths, regulatory nuances, and supply chain advantages across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape where biologics development activities concentrate and how organizations structure their global operations. In the Americas, innovation hubs and a dense ecosystem of clinical trials create sustained demand for clinical manufacturing and rapid analytics, while regulatory frameworks emphasize data integrity and process validation practices that support accelerated development pathways. This region also benefits from proximity to major sponsors and venture capital, which reinforces a pipeline of early-stage programs requiring specialized contract development support.

Europe, the Middle East & Africa features diverse regulatory environments and a mix of established biomanufacturing clusters alongside emerging capabilities. In several European markets, incentives for bioproduction and investments in advanced manufacturing infrastructure support the adoption of continuous processing and single-use technologies. Regional collaboration initiatives and harmonization efforts can reduce barriers for cross-border supply, but organizations must still navigate differing national requirements and logistics complexities when planning multi-site development and commercial supply strategies.

Asia-Pacific continues to expand its role as both a manufacturing base and an innovation center, with notable growth in contract manufacturing capacity, investments in single-use systems, and an increasing number of facilities certified to international regulatory standards. The region's supply chain strengths, including components and consumables manufacturing, offer advantages for sponsors seeking diversified sourcing and competitive cost structures. However, regulatory pathways and market access conditions vary substantially across jurisdictions, prompting sponsors and contract developers to build localized regulatory expertise and regional partnerships to ensure timely program progression and compliance.

Across regions, strategic choices will hinge on balancing access to talent, regulatory alignment, supply chain resilience, and proximity to clinical trial networks. Firms that develop regional playbooks tailored to these considerations will be better positioned to support sponsors across development stages and to respond to shifting policy and economic environments.

Critical competitive insights into how technology investment, regulatory depth, and geographic footprint create differentiation among contract development and manufacturing organizations

Competitive dynamics among contract development and manufacturing organizations are defined by differentiation in technology platforms, depth of regulatory experience, and the breadth of integrated services offered. Leading providers prioritize investments in advanced analytics, scalable single-use systems, and process intensification techniques to reduce cycle times and improve product quality consistency. These investments are often complemented by strategic partnerships and capability co-development arrangements that accelerate access to novel modalities and analytical methods.

Another axis of differentiation lies in quality systems and regulatory track records. Organizations with established compliance histories across major regulatory jurisdictions can facilitate smoother program transitions from clinical phases to commercial supply, which is particularly valuable for sponsors seeking global launches. In addition, providers that offer value-added services-such as comparability study design, stability testing strategies, and regulatory submission support-are increasingly preferred over purely transactional suppliers because they reduce coordination overhead and technical risk for sponsors.

Operational resilience and geographic footprint also play a critical role. Firms with multi-site capabilities can offer redundancy and surge capacity, which is crucial for vaccine programs or personalized therapies requiring rapid turnarounds. At the same time, niche specialists focused on particular modalities or host systems carve out defensible positions by developing deep technical expertise and proprietary process knowledge. Collectively, these strategic approaches define the competitive map and inform how sponsors select partners based on alignment to program complexity, timeline urgency, and long-term commercialization plans.

Actionable strategic recommendations for industry leaders to align technology investments, operational resilience, and partnership models for scalable biologics development

Industry leaders must adopt actionable strategies that reconcile innovation velocity with operational robustness to capture value in biologics development. First, prioritize technology roadmaps that balance continuous processing and single-use flexibility with selective investments in stainless steel systems where long-term high-volume production justifies the capital outlay. Align these technology choices with product portfolios and anticipated lifecycle requirements to avoid stranded assets and ensure scalable capacity.

Second, build cross-functional governance mechanisms that bring procurement, quality, regulatory, and operations together early in program planning. This integrated approach reduces handoff risks, shortens decision cycles, and creates clearer escalation paths for technical issues. Third, enhance supplier diversity by qualifying alternate vendors for critical consumables and equipment, and by establishing regional sourcing strategies that mitigate tariff and logistics exposures. Combined with scenario-based inventory strategies, these actions strengthen supply chain resilience.

Fourth, invest in talent and process knowledge transfer programs that accelerate sponsor-partner integration, particularly for complex modalities such as cell and gene therapies and novel antibody constructs. This includes structured training, collaborative development sprints, and shared analytics platforms that preserve institutional knowledge and enable rapid troubleshooting. Finally, adopt partnership models that align incentives around long-term product success, including risk-sharing arrangements for scale-up and commercialization phases. These practical steps will enable organizations to reduce technical risk, accelerate timelines, and capture strategic value from emerging biologics opportunities.

A transparent, multi-source research methodology combining expert interviews, technical literature synthesis, and operational assessment to ensure actionable analysis

The research approach underpinning this analysis combines qualitative expert interviews, technical literature synthesis, and cross-functional operational assessment to ensure a robust and actionable perspective. Primary inputs included discussions with process development scientists, manufacturing leaders, regulatory affairs professionals, and supply chain experts, which provided firsthand insight into current pain points, technology adoption patterns, and regional operational differences. These conversations were structured to surface both tactical challenges and strategic imperatives across clinical and commercial stages.

Secondary research focused on technical publications, regulatory guidance documents, and publicly available case studies that illustrate best practices in process intensification, facility design, and quality systems. Emphasis was placed on triangulating findings across sources to validate trends and to identify areas of divergence between reported capabilities and operational realities. Analytical frameworks were applied to assess technology maturity, supply chain exposure, and the alignment of end-user needs with provider offerings.

Throughout the research process, care was taken to ensure transparency of assumptions and to document methodological limitations. Where gaps existed in public information, targeted expert validation helped refine interpretations and reduce uncertainty. The result is a synthesis that balances technical rigor with practical relevance, providing executives with clear diagnostic insight and a tested set of strategic considerations to guide decision-making in biologics contract development.

A conclusive synthesis highlighting imperative focus areas for leaders to secure resilient, scalable, and commercially viable biologics development pathways

In conclusion, the biologics contract development environment is at an inflection point where technological innovation, regulatory complexity, and geopolitical shifts converge to reshape strategic decision-making. Sponsors and providers who align technology investments with product modality demands, who strengthen cross-functional governance, and who diversify supply chains will navigate this period with greater agility and lower operational risk. The ability to integrate process development, clinical manufacturing, and commercial readiness into cohesive program plans will determine which organizations accelerate timelines and capture value.

Looking ahead, success will favor those who adopt adaptive facility designs, invest in advanced analytics, and cultivate partnerships that share both expertise and risk. Regional strategies should be calibrated to regulatory realities and supply chain advantages, and contingency planning should account for policy-driven disruptions such as tariff adjustments. By focusing on these core imperatives, industry leaders can translate emerging trends into durable competitive advantage and ensure resilient pathways from discovery through commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development Market, by Service Type

  • 8.1. Clinical Manufacturing
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Commercial Manufacturing
  • 8.3. Fill Finish
  • 8.4. Process Development
    • 8.4.1. Downstream Development
    • 8.4.2. Upstream Development

9. Biologics Contract Development Market, by Molecule Type

  • 9.1. Cell Gene Therapy
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Bispecific
    • 9.2.2. Conjugated
    • 9.2.3. Naked
  • 9.3. Recombinant Proteins
  • 9.4. Vaccines
    • 9.4.1. Bacterial
    • 9.4.2. Mrna
    • 9.4.3. Viral

10. Biologics Contract Development Market, by Therapeutic Area

  • 10.1. Autoimmune Disorders
  • 10.2. Cardiovascular
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Oncology
    • 10.4.1. Hematology
    • 10.4.2. Solid Tumors

11. Biologics Contract Development Market, by Host System

  • 11.1. Mammalian
    • 11.1.1. Cho Cells
    • 11.1.2. Ns0 Cells
  • 11.2. Microbial
  • 11.3. Yeast

12. Biologics Contract Development Market, by Technology

  • 12.1. Continuous Manufacturing
    • 12.1.1. Perfusion
    • 12.1.2. Single Pass
  • 12.2. Single Use Systems
  • 12.3. Stainless Steel Systems

13. Biologics Contract Development Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Contract Manufacturing Organizations
  • 13.3. Pharmaceutical Companies

14. Biologics Contract Development Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Contract Development Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Contract Development Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biologics Contract Development Market

18. China Biologics Contract Development Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie, Inc.
  • 19.6. Abzena Ltd.
  • 19.7. Aenova Holding GmbH
  • 19.8. AGC Biologics GmbH
  • 19.9. Avid Bioservices, Inc.
  • 19.10. Binex Co. Limited
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Cambrex Corporation
  • 19.13. Catalent, Inc.
  • 19.14. Emergent BioSolutions, Inc.
  • 19.15. Fujifilm Holdings Corporation
  • 19.16. Icon PLC
  • 19.17. JRS PHARMA GmbH & Co. KG
  • 19.18. JSR Life Sciences, LLC
  • 19.19. Lonza Group AG
  • 19.20. Parexel International Corporation
  • 19.21. ProBioGen AG
  • 19.22. Recipharm AB
  • 19.23. Rentschler Biopharma SE
  • 19.24. Samsung Biologics
  • 19.25. Takeda Pharmaceutical Company Limited
  • 19.26. Thermo Fisher Scientific, Inc.
  • 19.27. Toyobo Co., Ltd.
  • 19.28. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 276. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 277. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 280. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)

TAB